

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

SCHERING-PLOUGH LEGISLATIVE RESOURCES L.L.C.

2. Address:

1130 CONNECTICUT AVE., NW SUITE 500, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

Country: _____ City: _____ State/Zip(or Country): _____

4. Contact Name: MARRA BUSSEY

Telephone: 202-463-7372

E-mail (optional): marra.bussey@spcorp.com

Senate ID #: 34502-12

House ID #: 33570000

7. Client Name: Self

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 920,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: SCHERING-PLOUGH LEGISLATIVE RESOURCES LLC. Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: AGR (one per page)

16. Specific lobbying issues:

H.R.1254, National Farm Animal Identification and Records Act; H.R.3170, To establish a Livestock Identification Board to create and implement a mandatory national livestock identification system. Legislative proposals related to a national animal identification program; H.R.1254, National Farm Animal Identification and Records Act; H.R.3170, To establish a Livestock Identification Board to create and implement a mandatory national livestock identification system.

17. House(s) of Congress and Federal agencies contacted:

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: EHRLICH, PAUL

Covered Official Position (if applicable):

Name: LIVELY, ROBERT

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: SCHERING-PLOUGH LEGISLATIVE RESOURCES L.L.C. Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: ANI (one per page)

16. Specific lobbying issues:

H.R.1254, National Farm Animal Identification and Records Act; H.R.2744, Fiscal 2006 Agriculture Appropriations; H.R.3170, To establish a Livestock Identification Board to create and implement a mandatory national livestock identification system. Legislative proposals to implement and fund a national identification system, and/or country of origin labeling; H.R.1254, National Farm Animal Identification and Records Act; H.R. 3170, To establish a Livestock Identification Board to create and implement a mandatory national livestock identification. Legislative proposals to affect US frequency standards for animal micro-chips: H.R.2744, Fiscal 2006 Agriculture Appropriations.

17. House(s) of Congress and Federal agencies contacted:

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: EHRlich, PAUL

Covered Official Position (if applicable):

Name: LIVELY, ROBERT

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.CON.RES.75, Expressing the sense of the congress that the illegal importation of prescription drugs severely undermines the regulatory protections afforded to the United States consumers, and for other purposes; H.R.1056, Methamphetamine Precursor Control Act of 2005; H.R.13, Clean, Learn, Educate, Abolish, Neutralize, and Undermine Production (CLEAN-UP) of Methamphetamine Act; H.R.1350, Methamphetamine Blister Pack Loophole Elimination Act of 2005; H.R.152, Preserving Access to Affordable Drugs Act of 2005; H.R.1572, Preserving Access to Affordable Drugs Act of 2005; H.R.1626, Medicare Prescription Drug Improvement Act; H.R.1669, Pharmacy Benefit Manager Transparency Act of 2005; H.R.2335, Meth-Endangered Children Protection Act of 2005; H.R.313, Exile Meth Act; H.R.314, Combat Meth Act of 2005; H.R.3199, Patient Act Reauthorization; H.R.328, Pharmaceutical Market Access Act of 2005; H.R.3324, Arrest Methamphetamine Act of 2005; H.R.3889, The Methamphetamine Elimination Act; H.R.3970, Bioterror Pandemic Preparedness Protection Act; H.R.4062, Pandemic Preparedness Response Act; H.R.4603, Pandemic Seasonal Influenza Act of 2005; H.R.4660, Requiring Emergency Pharmaceutical Access for Individual Relief (REPAIR) Act of 2006; H.R.4663, Authorize the Secretary of HHS to Reimburse States for Expenditures Associated with the Implementation of the Medicare Prescription Drug Benefit for Dual Eligible Individuals; H.R.4665, Amend Title XIX of the Social Security Act to Provide for an Offset from the Medicaid Clawback for State Emergency Prescription Drug Expenditures for Medicare Dual-Eligible Individuals; H.R.4675, Medicare State Reimbursement Act of 2006; H.R.4685, Medicare Prescription Drug Emergency Guarantee Act of 2006; H.R.4715, Amend Title XVIII of the Social Security Act to Extend the 2006 Annual Coordinated Election Period for Medicare Prescription Drug Plans through August 15, 2006; H.R.4719, Patients Before Profits Act of 2006; H.R.4721, Require Secretary of HHS To Provide Federal Medicaid for State Costs Associated with Ensuring Access to Prescription Drug Benefits to Part D Eligible Individuals; H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005; H.R.417, Medical Innovation Prize Act of 2005; H.R.752, Medicare Prescription Drug Savings and Choice Act of 2005; H.R.798, Methamphetamine Remediation Act of 2005; H.R.870, Pharmaceutical research and Manufacturers Accountability Act of 2005, PhRMA Act of 2005; S.103, Combat Meth Act of 2005; S.109, Pharmaceutical Market Access Act of 2005; S.1128, Pharmaceutical Advertising and Prudent Purchasing Act; S.1361, A bill to amend the Controlled Substances Act to treat drug offenses involving crystal meth similarly to drug offenses involving crack cocaine; S.1437, Bioterror Pandemic Preparedness Protection Act; S.1821, Pandemic Preparedness Response Act; S.1873, Biodefense Pandemic Vaccine Drug Development Act of 2005; S.1880, National Biodefense Pandemic Preparedness Act of 2005; S.334, Pharmaceutical Market Access and Drug Safety Act of 2005; S.354, HEALTH Act of 2005, Health Efficient, Accessible, Low-Cost, timely Healthcare Act of 2005; S.764, Preserve Access to Affordable Drugs Act of 2005; S.873, Medicare Prescription drug Savings and Choice Act of 2005; S.930, Food and Drug Administration Safety Act of 2005. Legislation controlling access to precursor chemicals for meth production and/or combating meth: H.R.1056, Methamphetamine Precursor Control Act of 2005; H.R.13, Clean, Learn, Educate, Abolish, Neutralize, and Undermine Production (CLEAN-UP) of Methamphetamine Act; H.R.1350, Methamphetamine Blister Pack Loophole Elimination Act of 2005; H.R.2335, Meth-Endangered Children Protection Act of 2005; H.R.313, Exile Meth Act; H.R.314, Combat Meth Act of 2005; H.R.3199, Patient Act Reauthorization; H.R.328, Pharmaceutical Market Access Act of 2005; H.R.3324, Arrest Methamphetamine Act of 2005; H.R.3889, The Methamphetamine Elimination Act; H.R.798, Methamphetamine Remediation Act of 2005; S.103, Combat Meth Act of 2005; S.1361, A bill to amend the Controlled Substances Act to treat drug offenses involving crystal meth similarly to drug offenses involving crack cocaine. Legislation regarding access to prescription drugs: H.CON.RES.75, Expressing the sense of the congress that the illegal importation of prescription drugs severely undermines the regulatory protections afforded to the United States consumers, and for other purposes; H.R.152, Preserving Access to Affordable Drugs Act of 2005; H.R.1572, Preserving Access to Affordable Drugs Act of 2005; H.R.1626, Medicare Prescription Drug Improvement Act; H.R.1669, Pharmacy Benefit Manager Transparency Act of 2005; H.R.328, Pharmaceutical Market Access Act of 2005; H.R.417, Medical Innovation Prize Act of 2005; H.R.4660, Requiring Emergency Pharmaceutical Access for Individual Relief (REPAIR) Act of 2006; H.R.4663, Authorize the Secretary of HHS to Reimburse States for Expenditures Associated with the Implementation of the Medicare Prescription Drug Benefit for Dual Eligible Individuals; H.R.4665, Amend Title XIX of the Social Security Act to Provide for an Offset from the Medicaid Clawback for State Emergency Prescription Drug Expenditures for Medicare Dual-Eligible Individuals; H.R.4675, Medicare State Reimbursement Act of 2006; H.R.4685, Medicare Prescription Drug Emergency Guarantee Act of 2006; H.R.4715, Amend Title XVIII of the Social Security Act to Extend the 2006 Annual Coordinated Election Period for Medicare Prescription Drug Plans through August 15, 2006; H.R.4719, Patients Before Profits Act of 2006; H.R.4721, Require Secretary of HHS To Provide Federal Medicaid for State Costs Associated with Ensuring Access to Prescription Drug Benefits to Part D Eligible Individuals; H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005; H.R.752, Medicare Prescription Drug Savings and Choice Act of 2005; H.R.870, Pharmaceutical research and Manufacturers Accountability Act of 2005, PhRMA Act of 2005; S.109, Pharmaceutical Market Access Act of 2005; S.1128, Pharmaceutical Advertising and Prudent Purchasing Act; S.334, Pharmaceutical Market Access and Drug Safety Act of 2005; S.354, HEALTH Act of 2005, Health Efficient, Accessible, Low-Cost, timely Healthcare Act of 2005; S.764, Preserve Access to Affordable Drugs Act of 2005; S.873, Medicare Prescription drug Savings and Choice Act of 2005; S.930, Food and Drug Administration Safety Act of 2005. Legislation regarding pandemic vaccine production: H.R.3970, Bioterror Pandemic Preparedness Protection Act; H.R.4062, Pandemic Preparedness Response Act; H.R.4603, Pandemic Seasonal Influenza Act of 2005; S.1437, Bioterror Pandemic Preparedness Protection Act; S.1821, Pandemic Preparedness Response Act; S.1873, Biodefense Pandemic Vaccine Drug Development Act of 2005; S.1880, National Biodefense Pandemic Preparedness Act of 2005.

17. House(s) of Congress and Federal agencies contacted:

Registrant Name: SCHERING-PLOUGH LEGISLATIVE RESOURCES LLC. Client Name: Self

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY
Covered Official Position (if applicable):
Name: EHRLICH, PAUL
Covered Official Position (if applicable):
Name: LIVELY, ROBERT
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: SCHERING-PLOUGH LEGISLATIVE RESOURCES LLC. Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R.3971, Medicare Cost Sharing and Welfare Extension Act of 2005; H.R.4241, Deficit Reduction Act of 2005. Legislative proposals to ban Medicare and Medicaid reimbursement for erectile dysfunction drugs: H.R. 3971, Medicare Cost Sharing and Welfare Extension Act of 2005. Amendments and bill language related to changes in Medicare reimbursement to pharmacies for prescription drugs and changes to Medicaid best price rebate: H.R.4241, Deficit Reduction Act of 2005.

17. House(s) of Congress and Federal agencies contacted:

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY

Covered Official Position (if applicable):

Name: EHRLICH, PAUL

Covered Official Position (if applicable):

Name: LIVELY, ROBERT

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: SCHERING-PLOUGH LEGISLATIVE RESOURCES LLC. Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

H.R.2077, To suspend temporarily the duty on Garenoxacin mesylate; H.R.2079, To extend the temporary duty suspension on Ezetimibe; S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005. Legislation regarding duty suspension for Ezetimibe: H.R.2077, To suspend temporarily the duty on Garenoxacin mesylate; H.R.2079, To extend the temporary duty suspension on Ezetimibe; S.1551, Protecting Free Trade in Pharmaceuticals Act of 2005.

17. House(s) of Congress and Federal agencies contacted:

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY

Covered Official Position (if applicable):

Name: EHRLICH, PAUL

Covered Official Position (if applicable):

Name: LIVELY, ROBERT

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 14, 2006

Printed Name and Title: Marra Bussey, Associate, Corporate Government Affa -